<DOC>
	<DOCNO>NCT01367522</DOCNO>
	<brief_summary>This multicenter , non-randomized , single-dose , parallel-group study . Each subject receive subcutaneous dose MNTX . Eight subject normal hepatic function eight subject classification hepatic impairment enrol . Plasma sample collect specified interval dose concentration MNTX analyze .</brief_summary>
	<brief_title>Pharmacokinetics , Safety , Tolerability Methylnaltrexone Volunteers With Impaired Hepatic Function</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Methylnaltrexone</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>1 . Males female age 1880 year 2 . Body weight great 100 lb BMI 1838 3 . Liver value abnormal must clinically relevant judged investigator . Liver enzyme bilirubin must less 5 time upper normal reference range may repeat fed condition abnormal . Stable hepatitis patient well cirrhosis patient either etiology . 1 . History current alcohol abuse le 1 year abstinence 2 . Conditions possibly affect drug absorption , e.g . gastrectomy clinically significant diabetic gastroenteropathy . 3 . Currently pregnant nursing 4 . Methadone use .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>